SCHEMBL435617

SCHEMBL435617

CC(CO)N(CC(=O)O)C(C)CO

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.36
EYA2 O00167 1/20 0.36
APP P05067 1/20 0.36
ACE P12821 1/20 0.36
TSHR P16473 2/20 0.35
KDM4E B2RXH2 1/20 0.35
LMNA P02545 1/20 0.35
CHRM2 P08172 1/20 0.35
ADRA2A P08913 1/20 0.35
ALOX15 P16050 1/20 0.35
DRD1 P21728 1/20 0.35
SLC6A2 P23975 1/20 0.35
SLC6A4 P31645 1/20 0.35
CYP2C19 P33261 1/20 0.35
ADRA1A P35348 1/20 0.35
DRD3 P35462 1/20 0.35
BLM P54132 1/20 0.35
PMP22 Q01453 1/20 0.35
SLC6A3 Q01959 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15284072 0.80 FFAR3 (0.36) TDP1EYA2APPACETSHR
SCHEMBL3743471 0.76 TDP1 (0.33) TDP1EYA2APPACETSHR
SCHEMBL8948418 0.76 CA2 (0.41) KDM4ELMNAALOX15
SCHEMBL867976 0.76 TDP1 (0.41) TDP1EYA2APPACETSHR
Hydrochloric Acid SCHEMBL5577032 0.74 TDP1 (0.39) TDP1EYA2APPACETSHR
SCHEMBL186528 0.74 TDP1 (0.39) TDP1EYA2APPACETSHR
SCHEMBL8948341 0.74 TDP1 (0.39) TDP1EYA2APPACETSHR
SCHEMBL30786609 0.73 FOLH1 (0.41) TDP1TSHRLMNABLMCYP1A2
SCHEMBL676800 0.72 GABRP (0.42) TDP1EYA2APPACEGABRP
SCHEMBL3901854 0.72 TDP1 (0.38) TDP1EYA2APPACETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3621735-A1 PROTECTIVE SURFACE COATINGS FOR FLOW CELLS Illumina, Inc. (US) 2020-03-18 EP claimed
WO-2019058318-A1 Formulations to administer SUMO2/3 PLICO BIOTECH INC. (US) 2019-03-28 WO claimed
EP-3411077-A1 EFFICIENT PROCESS FOR PREPARING CELL-BINDING AGENT-CYTOTOXIC AGENT CONJUGATES ImmunoGen, Inc. (US) 2018-12-12 EP claimed
WO-2018208561-A1 PROTECTIVE SURFACE COATINGS FOR FLOW CELLS ILLUMINA, INC. (US) 2018-11-15 WO claimed
WO-2017136623-A1 EFFICIENT PROCESS FOR PREPARING CELL-BINDING AGENT-CYTOTOXIC AGENT CONJUGATES IMMUNOGEN, INC. (US) 2017-08-10 WO claimed
US-5574050-A Hydroxyl ions as unique therapeutic agents and processes for preparing them FHJ SCIENTIFIC, INC. (US) 1996-11-12 US claimed
EP-0725636-A1 HYDROXYL IONS AS UNIQUE THERAPEUTIC AGENTS AND COMPOUNDS THAT MODULATE THESE IONS, COMPOSITIONS EMPLOYING THESE AGENTS, THERAPEUTIC METHODS FOR USING SUCH AGENTS AND PROCESSES FOR PREPARING THEM FHJ SCIENTIFIC, INC. (US) 1996-08-14 EP claimed
US-5514808-A Hydroxyl ions as unique therapeutic agents and compounds that modulate these ions FHJ SCIENTIFIC, INC (US) 1996-05-07 US claimed
WO-1995010272-A1 HYDROXYL IONS AS UNIQUE THERAPEUTIC AGENTS AND COMPOUNDS THAT MODULATE THESE IONS, COMPOSITIONS EMPLOYING THESE AGENTS, THERAPEUTIC METHODS FOR USING SUCH AGENTS AND PROCESSES FOR PREPARING THEM FHJ SCIENTIFIC, INC. (US) 1995-04-20 WO claimed
EP-0158556-B1 PROCESS FOR THE PREPARATION OF HYDROXYALKYLAMINOACETIC ACIDS SOCIETE FRANCAISE HOECHST Société anonyme dite: (FR) 1987-07-01 EP claimed
EP-4221680-A1 PREPARATION AND STORAGE OF LIPOSOMAL RNA FORMULATIONS SUITABLE FOR THERAPY BioNTech SE (DE) 2023-08-09 EP disclosed
EP-4126069-A1 RNA PARTICLES COMPRISING POLYSARCOSINE BioNTech SE (DE) 2023-02-08 EP disclosed
US-20220287949-A1 SAFE PARTICLES FOR THE INTRODUCTION OF USEFUL CHEMICAL AGENTS IN THE BODY WITH CONTROLLED ACTIVATION BAMBU VAULT LLC (US) 2022-09-15 US disclosed
EP-3997140-A1 TWO-COMPONENT SYSTEM FOR THE IN SITU PREPARATION OF AN ARTIFICIAL CARTILAGE Heraeus Medical GmbH (DE) 2022-05-18 EP disclosed
EP-3993835-A1 RNA FORMULATIONS SUITABLE FOR THERAPY BioNTech SE (DE) 2022-05-11 EP disclosed
US-5574050-A Hydroxyl ions as unique therapeutic agents and processes for preparing them FHJ SCIENTIFIC, INC. (US) 1996-11-12 US disclosed
EP-0725636-A1 HYDROXYL IONS AS UNIQUE THERAPEUTIC AGENTS AND COMPOUNDS THAT MODULATE THESE IONS, COMPOSITIONS EMPLOYING THESE AGENTS, THERAPEUTIC METHODS FOR USING SUCH AGENTS AND PROCESSES FOR PREPARING THEM FHJ SCIENTIFIC, INC. (US) 1996-08-14 EP disclosed
US-5514808-A Hydroxyl ions as unique therapeutic agents and compounds that modulate these ions FHJ SCIENTIFIC, INC (US) 1996-05-07 US disclosed
WO-1995010272-A1 HYDROXYL IONS AS UNIQUE THERAPEUTIC AGENTS AND COMPOUNDS THAT MODULATE THESE IONS, COMPOSITIONS EMPLOYING THESE AGENTS, THERAPEUTIC METHODS FOR USING SUCH AGENTS AND PROCESSES FOR PREPARING THEM FHJ SCIENTIFIC, INC. (US) 1995-04-20 WO disclosed
EP-0158556-A1 Process for the preparation of hydroxyalkylaminoacetic acids SOCIETE FRANCAISE HOECHST Société anonyme dite: (FR) 1985-10-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220287949-A1 SAFE PARTICLES FOR THE INTRODUCTION OF USEFUL CHEMICAL AGENTS IN THE BODY WITH CONTROLLED ACTIVATION MPO, CUTA, LPO TDP1 2693/4885EYA2 1916/4885APP 2377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.